ArticlePloS one2020
Effect of antibiotic gut microbiota disruption on LPS-induced acute lung inflammation.
Article in PloS one, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Investigation of Oral Toxicity Mechanisms of Low-Molecular-Weight Polycyclic Aromatic Hydrocarbons and Probiotic Interventions Under the Framework of the "Gut-Lung Axis".Foods (Basel, Switzerland) · 2026Review
- Immune dysregulation and gut microbiota: Connection to health and disease development.Neural regeneration research · 2026Article
- The gut-lung axis in ARDS: beyond microbial translocation.Respiratory research · 2026Review
- Veterinary Drug Residues in Food Chains: Sources, Exposure Pathways, Health Impacts, Mitigation, and Safety Assurance.Foods (Basel, Switzerland) · 2026Review
- Gut microbiota and metabolites in acute lung injury: mechanisms and therapeutic perspectives.Respiratory research · 2026Review
- Gut microbiota-regulated cell death: a review on pyroptosis, ferroptosis, and related mechanisms.Frontiers in microbiology · 2026Review
- Gut microbiota in acute lung injury/acute respiratory distress syndrome: mechanistic insights and therapeutic opportunities via the gut-lung axis.Frontiers in cellular and infection microbiology · 2026Review
- Gut microbiome and lung cancer: mechanisms, interactions, and dietary interventions.Gut microbes reports · 2025Review
- Preventive Effect of the Total Polyphenols fromInternational journal of molecular sciences · 2024Article
- Gut microbiota and its metabolic products in acute respiratory distress syndrome.Frontiers in immunology · 2024Review
- What Makes the Gut-Lung Axis Working? From the Perspective of Microbiota and Traditional Chinese Medicine.The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale · 2024Review
- Impact of Intensive Care Unit Nutrition on the Microbiome and Patient Outcomes.Anesthesiology clinics · 2023Review
- Orally administered Odoribacter laneus improves glucose control and inflammatory profile in obese mice by depleting circulating succinate.Microbiome · 2022Article
- Long-distance relationships - regulation of systemic host defense against infections by the gut microbiota.Mucosal immunology · 2022Review
- Intestinal Microbiota - An Unmissable Bridge to Severe Acute Pancreatitis-Associated Acute Lung Injury.Frontiers in immunology · 2022Review
- Article
- In Vitro Modulatory Effect of Stevioside, as a Partial Sugar Replacer in Sweeteners, on Human Child Microbiota.Microorganisms · 2021Article
- The Role of Gut Microbiota in Lung Cancer: From Carcinogenesis to Immunotherapy.Frontiers in oncology · 2021Review
- Impact of fecal microbiota transplantation on lung function and gut microbiome in an ARDS rat model: A multi-omics analysis including 16S rRNA sequencing, metabolomics, and transcriptomics.International journal of immunopathology and pharmacologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAn increasing body of evidence is indicating that the gut microbiota modulates pulmonary inflammatory responses. This so-called gut-lung axis might be of importance in a whole spectrum of inflammatory pulmonary diseases such as acute respiratory distress syndrome, chronic obstructive pulmonary disease and pneumonia. Here, we investigate the effect of antibiotic disruption of gut microbiota on immune responses in the lung after a intranasal challenge with lipopolysaccharide (LPS). METHODS/
resultsC57Bl/6 mice were treated for two weeks with broad-spectrum antibiotics supplemented to their drinking water. Afterwards, mice and untreated control mice were inoculated intranasally with LPS. Mice were sacrificed 2 and 6 hours post-challenge, after which bronchoalveolar lavage fluid (BALF) and lung tissues were taken. Gut microbiota analysis showed that antibiotic-treated mice had a pronounced reduction in numbers and diversity of bacteria. A modest, but time consistent, significant increase of interleukin (IL)-6 release was seen in BALF of antibiotic treated mice. Release of tumor necrosis factor alpha (TNFα), however, was not statistically different between groups.
conclusionAntibiotic induced microbiota disruption is associated with alterations in host responses during LPS-induced lung inflammation. Further studies are required to determine the clinical relevance of the gut-lung axis in pulmonary infection and inflammation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.